Andrew A. Lane, MD, PhD


Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCN

Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.

Sanjay K. Juneja, MD


Juneja Reflects on Becoming a Targeted Oncology 2024 Oncology Icon

Sanjay K. Juneja, MD, delves into what being recognized as an oncology icon for Targeted Oncology means to him.

Mwanasha Merrill


PD-1 Blockade and Transplant as a Potential New Treatment in PTCL

Mwanasha Merrill discusses results from a phase 2 study which evaluated PD-1 blockade post autologous stem cell transplantation with pembrolizumab in patients with peripheral T-cell lymphoma.

Brendon Stiles, MD


Exploring the Importance of Finding a Molecular Target in Lung Cancer

Brendon Stiles, MD, discusses the current landscape for treating patients with metastatic lung cancer.

Jens Hillengass, MD, PhD


Key Takeaways on Recent Data in Multiple Myeloma from ASH 2023

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.

Sandra Toogood, BPharm


Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

According to Joshua M. Lang, MD, MS, the importance of molecular understanding, especially in initially focusing on the genetics of PCa and how that can inform new therapies, has been one of the revolutions in PCa.

Crystal Ritchey, PhD


Risk-Based Treatment of Hodgkin Lymphoma in the Era of Novel Therapies

Despite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma.

Amir Khan, MD


Study Investigators Question the Rise of CRC in Young Adult Patients

Amir Khan, MD, discusses the possible reasons for the rising incidence of young adult patients with gastric cancer and colorectal cancer at the 2020 Gastrointestinal Cancers Symposium.

Bhavana Pothuri, MD


Metastatic Endometrial Cancer: Future Directions in Care

Closing out her discussion on the management of recurrent metastatic endometrial cancer, Bhavana Pothuri, MD, highlights ongoing clinical trials and novel treatment modalities.

Hannah Clarke


Survival Benefit Shown With Niraparib Plus Abiraterone in BRCA+ mCRPC

Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

Thomas Habermann, MD


Polatuzumab Vedotin Plus R-CHOP May Improve Outcomes For DLBCL Patients

Thomas Habermann, MD, discusses R-CHOP and how it can be improved upon as a treatment method for diffuse large B-cell lymphoma.

Lucy Gilbert, MD, MSc


Mirvetuximab Soravtansine Combination Improves Responses in Platinum-Agnostic Ovarian Cancer

Lucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.

Sairah Ahmed, MD


Research Ongoing for CAR T-Cell Therapy Axi-Cel in Lymphoma

Sairah Ahmed, MD, discusses the continued investigations of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy used in multiple types of lymphoma.

Asutosh Gor, MD


Germline Testing Outside the Guidelines: Can it Address Health Disparities?

The completion of the Human Genome project has ushered in a new era in our understanding of cancer.

Anita Kumar, MD


What Is High-Risk Mantle Cell Lymphoma, and How Should We Treat It?

Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.

Nirav N. Shah, MD


Pirtobrutinib Produces Durable Responses in Pretreated MCL

Nirav Shah, MD, discusses long-term data from the phase 1/2 BRUIN study which evaluated pirtobrutinib in mantle cell lymphoma, and next steps for evaluating the agent.

Paula Rodriguez-Otero, MD, PhD


Ide-cel Significantly Prolongs PFS in KarMMa-3 Trial for Multiple Myeloma

Paula Rodriguez-Otero, MD, PhD, provides an overview of the phase 3 KarMMa-3 trial of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Igor Astsaturov, MD, PhD


Astsaturov on the Phase 1 Study of LP-184 in Advanced Solid Tumors

Igor Astsaturov, MD, PhD, discusses the planned phase 1 trial of LP-184 in multiple advanced solid tumors and central nervous system cancers, including pancreatic cancer.

Yann-Alexandre Vano, MD


Vano Highlights Trials and Data in RCC

Yann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.

Sophia Kamran, MD


Anticipating Expanded Uses of Radiotherapy in Urothelial Carcinoma

Sophia Kamran, MD, discusses future roles that radiation oncology will play in combination with resection and targeted therapy in urothelial carcinoma.

Jane Mendez, MD, PhD


Challenges of Breast Cancer in Young Adults

According to Jane Méndez, M.D., FACS, special considerations come into play when diagnosing and treating young adults with breast cancer.

Leora Horn, MD, MSc


NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy

Leora Horn, MD, MSc, discusses the data accrued from Flatiron and from a phase 1/2 trial of patients with refractory non–small cell lung cancer with EGFR exon 20 insertions receiving mobocertinib compared with currently approved therapies.

Catherine J. Lee, MD, MS


Severe, Multi-Organ Chronic Graft-versus- Host Disease (cGvHD): Diagnosis and Initial Treatment Approach

This segment covers the diagnosis and initial treatment of a case of severe, multi-organ cGvHD, including the use of high-dose corticosteroids and other systemic agents.

Jeffrey Aldrich, MD


Management of HR+, HER2- Early-Stage Breast Cancer After Diagnosis

Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.

Daneng Li, MD


Choosing Second-Line Therapy for HCC After Atezolizumab/Bevacizumab

Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.

Stephanie L. Wethington, MD, MSc


PARP Inhibitor-Resistant Ovarian Cancer Responds to PARP Plus ATR Inhibitors

Stephanie L. Wethington, MD, MSc, discusses results of a study of olaparib plus ceralasertib for overcoming resistance to PARP inhibition.

Hans C. Lee, MD


Managing Toxicity Seen With Linvoseltamab in R/R Multiple Myeloma

Hans C. Lee, MD, discusses the toxicity seen with the BCMA/CD3 bispecific antibody linvoseltamab for patients with relapsed/refractory multiple myeloma.